$16.90
1.74% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US0008991046
Symbol
ADMA

ADMA Biologics, Inc. Stock price

$16.90
-3.01 15.12% 1M
+1.07 6.76% 6M
-0.25 1.46% YTD
+0.33 1.99% 1Y
+14.09 501.42% 3Y
+14.67 657.85% 5Y
+8.10 92.05% 10Y
+8.35 97.66% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.30 1.74%
ISIN
US0008991046
Symbol
ADMA
Industry

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$4.0b
Net debt
positive
Cash
$90.3m
Shares outstanding
238.6m
Valuation (TTM | estimate)
P/E
19.9 | 28.9
P/S
8.5 | 7.8
EV/Sales
8.5 | 7.8
EV/FCF
61.2
P/B
10.1
Financial Health
Equity Ratio
71.4%
Return on Equity
56.6%
ROCE
32.2%
ROIC
53.7%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$474.2m | $516.4m
EBITDA
$155.8m | $222.7m
EBIT
$155.6m | $183.5m
Net Income
$208.9m | $139.3m
Free Cash Flow
$65.6m
Growth (TTM | estimate)
Revenue
43.6% | 21.1%
EBITDA
166.4% | 59.8%
EBIT
169.4% | 32.0%
Net Income
500.5% | -29.5%
Free Cash Flow
-0.8%
Margin (TTM | estimate)
Gross
53.0%
EBITDA
32.9% | 43.1%
EBIT
32.8%
Net
44.1% | 27.0%
Free Cash Flow
13.8%
More
EPS
$0.9
FCF per Share
$0.3
Short interest
7.7%
Employees
685
Rev per Employee
$620.0k
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a ADMA Biologics, Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
80%
Hold
20%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
474 474
44% 44%
100%
- Direct Costs 223 223
25% 25%
47%
251 251
65% 65%
53%
- Selling and Administrative Expenses 93 93
42% 42%
20%
- Research and Development Expense 2.66 2.66
29% 29%
1%
156 156
166% 166%
33%
- Depreciation and Amortization 0.11 0.11
84% 84%
0%
EBIT (Operating Income) EBIT 156 156
169% 169%
33%
Net Profit 209 209
501% 501%
44%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Positive
Seeking Alpha
about 24 hours ago
ADMA Biologics' earnings are surging due to higher plasma yield and a profitable shift toward premium IG brands, boosting margins. FDA approval of yield-enhancement technology increases finished IG output by 20%, driving efficiency and supporting ongoing revenue and margin growth. Expanded plasma sourcing and improved logistics de-risk supply, supporting long-term growth and simplifying distrib...
Positive
Seeking Alpha
25 days ago
ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output. This should help them with margin expansion beginning in 2026. ADMA also reaffirmed its guidance for over $500 million in 2025 revenues and over $625 million by 2026. ...
Positive
Seeking Alpha
27 days ago
ADMA Biologics experienced a significant stock pullback on Thursday after Q2 results, presenting a potential buying opportunity for investors. The company now operates 10 plasma collection centers and manufactures key products BIVIGAM and ASCENIV, supporting its solid growth outlook. The company recently announced a $500 million stock buyback program and initiated a new manufacturing process th...
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 685
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today